Hormonal
GLP-1 receptor agonists reduce cardiovascular events and atherosclerosis progression through weight-loss-independent anti-inflammatory mechanisms involving endothelial and immune cell modulation.
GLP-1 medications like semaglutide and liraglutide are proven to reduce the risk of heart attacks, strokes, and cardiovascular death in people with type 2 diabetes and obesity. This protection is partly due to direct anti-inflammatory effects on blood vessels, independent of weight loss. These benefits are significant enough to be a primary reason for prescribing these drugs in high-risk patients.
Treatment with 1 mg/kg liraglutide for 14 weeks reduced atherosclerotic plaque size in the aorta of Apoe–/– mice... Control mice with weight loss matching that of mice receiving 1 mg/kg liraglutide were not protected from atherosclerosis, suggesting that liraglutide has weight loss–independent anti-atherogenic effects.
Why this rating
Supported by large cardiovascular outcome trials and consistent preclinical data.
Source
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Chi Kin Wong et al. · Journal of Clinical Investigation · 2025
DOI 10.1172/jci194751
More from this paper
- GLP-1 receptor agonists (e.g., semaglutide, liraglutide) reduce systemic and tissue inflammation through mechanisms that are partially independent of weight loss and metabolic improvements.Good
- GLP-1 receptor agonists directly modulate immune cell function, specifically suppressing T-cell activity and pro-inflammatory cytokine release, independent of metabolic changes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →